Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Additional capacity broadens Grace’s fine chemical capabilities for API production
Subscribe To Our Newsletter & Stay Updated
